ASPB responds to Response to FDA-2015-N-3403: Clarifying Current Roles and Responsibilities Described in the Coordinated Framework for the Regulation of Biotechnology and Developing a Long-Term Strategy for the Regulation of the Products of Biotechnology; Request for Information. Since the first introduction of biotechnology-derived plant products, not a single documented issue with regard to human safety has … Read more
Dear Colleagues, As you know, there is substantial fear of GMO technology both within commercial and public spheres. Recently, companies like Chipotle and initiatives such as the Non-GMO Project (representing over 4,500 non-GMO brands) have cited a petition of 300 scientists that claim there is no consensus regarding the scientific safety of GMOs. A group of scientists and myself have organized a petition … Read more
The New York Times published the following letter to the editor from ASPB on October 30, 2015. ASPB’s letter was in response to the October 24th article by Mark Lynas, the political director for the Cornell Alliance for Science. In his piece, Lynas laments that due to “Europe’s Coalition of the Ignorant, we are witnessing … Read more
The White House Office has announced a major effort to update the Coordinated Framework for the Regulation of Biotechnology and they are seeking comments to inform the revisions. Because the federal comment website can be cumbersome, we will collect your comments here and submit them on your behalf. Your comments will become part of the … Read more
On October 16, the Food and Drug Administration (FDA) released a Request for Information (RFI) on “Clarifying Current Roles and Responsibilities Described in the Coordinated Framework for the Regulation of Biotechnology and Developing a Long-Term Strategy for the Regulation of the Products of Biotechnology” and announced a public meeting. This is the next step in … Read more